Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

Background:

- Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor that most frequently
involves skin, but can also involve lymph nodes, lungs and gastrointestinal tract. It is
most common in people with HIV or other forms of immune compromise. Patients with
AIDS-associated KS have worse survival than HIV-infected patients without KS.

- Patients may present with advanced disease KS and/or concurrent KSHV-associated
multicentric Castleman disease (MCD) or an IL-6 related KSHV-associated cytokine
syndrome (KICS). Patients with the latter conditions have poor outcomes when treated
with FDA-approved cytotoxic therapies used for KS, and novel approaches are needed.

- A Phase I/II Study demonstrated that pomalidomide 5 mg daily on days 1- 21 of a 28 Day
Cycle was safe and tolerable in patients with KS with or without HIV. Increased CD4+ and
CD8+ T-cell counts and KS regression were observed.

- Combination of pomalidomide with liposomal doxorubicin may offer a new approach for
patients with advanced KS or KS and concurrent KSHV-associated MCD or KICS

Objectives:

- Evaluate the safety and tolerability of various dose combinations of pomalidomide and
liposomal doxorubicin in two groups of patients: Group I) KS requiring systemic therapy;
Group II) KS with concurrent KSHV-associated MCD or KICS

- To assess the pharmacokinetics (PK) of pomalidomide in combination with liposomal
doxorubicin; and for patients with HIV in combination with antiretroviral therapy

Eligibility:

- Patients with biopsy proven (confirmed in the Laboratory of Pathology, CCR) Kaposi
sarcoma (KS)

- Group I: KS requiring systemic therapy (no prior therapy required)

- T1 KS, KS on skin sufficiently widespread that it is not amenable to local therapy,
or KS affecting quality of life due to local symptoms or psychological distress

OR

--KS patients with an inadequate response to pomalidomide (either progressive disease or
stable disease after 4 months)

OR

- KS patients with an inadequate response to liposomal doxorubicin, paclitaxel, or other
systemic chemotherapy (either progressive disease or stable disease after 6 cycles)

- Group I will exclude patients eligible for Group II (below).

- A wash out period off treatment of 3 weeks will be required, except in the case of
patients with progressive, severe disease in which delay of treatment cannot be
justified (i.e. symptomatic pulmonary KS)

-Group II: KS in one of the following high-risk groups (no prior therapy required):

- Concurrent KSHV-associated multicentric Castleman disease (MCD)

- KSHV Inflammatory Cytokine Syndrome (KICS), including those also meeting clinical
criteriafor KS immune reconstitution syndrome (KS IRIS) o Patients with primary effusion
lymphoma or a large cell lymphoma arising in KSHV-associated MCD are excluded.

- At least five measurable cutaneous KS lesions with no previous local radiation,
surgical or intralesional cytotoxic therapy that would prevent response assessment
for that lesion; or other evaluable disease.

- ECOG Performance Status (PS): Group I: less than or equal to 2, Group II: less than
or equal to 3, ECOG PS of 4 (with Karnofsky 20%) will be allowed in Group II only
if symptoms due to pulmonary KS.

- Measurable disease by the criteria proposed by the AIDS Clinical Trials Group
Oncology Committee (for KS).

- Patient or legal guardian must be willing to give informed consent.

- Patients can be HIV positive or negative.

- HAART for HIV+ patients.

Design:

- This is a Phase I study evaluating 2 groups of patients with KS. Patients will receive
pomalidomide once a day, days 1-21 of a 28-day cycle, at the various dose levels
combined with liposomal doxorubicin IV day 1 of a 28-day cycle until optimal tumor
response, unacceptable toxicity, or patient request to discontinue

- Patients with HIV will be prescribed HAART.

- All patients will receive thromboprophylaxis, generally with aspirin 81 mg tablet
daily.

- The study will proceed to an antitumor activity phase to assess in a preliminary manner
the response of Group I patients to a fixed dose of pomalidomide and liposomal
doxorubicin. Eighteen subjects (HIV positive or negative) evaluable for response will be
treated at the highest tolerable combination of pomalidomide and liposomal doxorubicin
(dose level 3: pomalidomide 4mg in combination with 20mg/m2 liposomal doxorubicin) to
gain preliminary information on antitumor activity.

- This study will also evaluate the characteristics of 18fluoro-thymidine (FLT) positron
emission tomography (PET) in patients with KS and concurrent KSHV-associated MCD or
KICS, and correlate with markers of KSHV-lytic activation

- INCLUSION CRITERIA:

- Patients must have histologically confirmed Kaposi sarcoma (KS) confirmed by the
Laboratory of Pathology, NCI.

- All patients should have either five measurable cutaneous KS lesions with no previous
local radiation, surgical or intralesional cytotoxic therapy that would prevent
response assessment for that lesion; or other assessable disease

- Group I: KS requiring systemic therapy (no prior therapy required) and:

- Group I patients should have one or more of the following:

- T1 KS, KS on skin sufficiently widespread that it is not amenable to local
therapy, or KS affecting quality of life due to local symptoms or psychological
distress

- KS patients with an inadequate response to pomalidomide (either progressive
disease or stable disease requiring additional therapy after 4 months)

- KS patients with an inadequate response to liposomal doxorubicin, paclitaxel, or
other systemic chemotherapy (either progressive disease or stable disease
requiring additional therapy after 6 cycles)

- Group I will exclude patients eligible for Group II (below). Patients with a
history of multicentric Castleman disease (MCD) in the absence of any active
disease (as assessed by the PI) are eligible for Group I.

- A wash out period off treatment of 3 weeks will be required, except in the
case of patients with progressive, severe disease in which delay of
treatment cannot be justified (i.e. symptomatic pulmonary KS)

- Group II: KS (no prior therapy required):

- Concurrent active KSHV-associated multicentric Castleman disease (MCD)

- Active KSHV Inflammatory Cytokine Syndrome (KICS), including those also meeting
clinical criteria for KS immune reconstitution syndrome (KS IRIS)

- At least five measurable cutaneous KS lesions with no previous local radiation,
surgical or intralesional cytotoxic therapy that would prevent response assessment for
that lesion; or other assessable disease

- ECOG Performance Status (PS):

- Group I: less than or equal to 2

- Group II: less than or equal to 3

- ECOG PS of 4 will be allowed in Group II only if symptoms due to pulmonary KS.
(with Karnofsky = 20%).

- Measurable disease by the criteria proposed by the AIDS Clinical Trials Group Oncology
Committee (for KS).

- Patients can be HIV positive or negative.

- HAART for HIV+ patients:

- All HIV+ patients must be willing to be compliant with HAART

- Group I-on HAART for 1 month with stable disease; however, no minimum time
restriction for patients with progressive and/or end-organ threatening disease

- Group II-no minimum time restriction on prior HAART, patients may be HAART naive.

- Age greater than or equal to18 years.

--Because no dosing or adverse event data are currently available on the use of
pomalidomide in combination with liposomal doxorubicin in patients <18 years of age,
children are excluded from this study, but may be eligible for future pediatric
trials.

- Patients must have normal organ and marrow function as defined below:

- Absolute neutrophil count greater than or equal to 1,000/mcL

- Platelets >75,000/mcL

- Hemoglobin

- Group I: greater than or equal to 8 gm/dL;

- Group II: if anemia attributed to KS, KSHV-MCD, or KICS greater than or
equal to 7gm/dL, otherwise greater than or equal to 8 gm/dL

- Total bilirubin less than or equal to1.5 upper limit of normal unless the patient
is receiving a protease inhibitor known to be associated with increased bilirubin
(e.g. atazanavir), in which case total bilirubin less than or equal to 7.5 mg/dL
with direct fraction less than or equal to 0.7

- AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of
normal

- Creatinine within normal institutional limits OR Creatinine clearance >60
mL/min/1.73 m(2) as estimated by either Cockroft-Gault or 24-hour urine
collection for patients with creatinine levels above institutional normal

- Cardiac ejection fraction greater than or equal to 50% by echocardiogram

- Patients with a cumulative lifetime history of anthracycline greater than 430 mg/m(2)
are eligible, after consultation with a cardiologist, if there are none of the
following cardiac risk factors:

- Diabetes mellitus

- History of acute coronary syndrome

- Hypertension; defined as a sustained systolic blood pressure greater than 140
mmHg and/or diastolic blood pressure greater than 90 mmHg OR use of an
antihypertensive medication for the indication of hypertension.

- All study participants must agree to be registered into the mandatory POMALYST REMS
program, and be willing and able to comply with the requirements of the POMALYST REMS
program

- Females of reproductive potential must adhere to the scheduled pregnancy testing as
required in the POMALYST REMSTM program

- Able to take aspirin 81mg daily or if intolerant of aspirin, able to take a substitute
thromboprophylaxis such as low molecular weight heparin at a thromboprophylactic dose
(such as enoxaparin 0.5mg/kg once daily)

- Because pomalidomide is an agent with the potential for teratogenic or abortifacient
effects, females of childbearing potential (FCBP) must have a negative serum or urine
pregnancy test with a sensitivity of at least 25 mIU/mL within 14 days prior to and
again within 24 hours before starting pomalidomide and must either commit to continued
abstinence from heterosexual intercourse or begin TWO acceptable methods of birth
control, one highly effective method and one additional effective method AT THE SAME
TIME, at least 28 days before she starts taking pomalidomide. FCBP must also agree to
ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact
with a FCBP even if they have had a vasectomy. All subjects must be counseled at a
minimum of every 28 days about pregnancy precautions and risks of fetal exposure.

- Ability of subject to understand and the willingness to sign a written informed
consent document.

EXCLUSION CRITERIA:

- Patients who are receiving any other investigational agents.

- Patients with primary effusion lymphoma or other concurrent malignancy, except for
basal cell carcinoma or squamous carcinoma of the skin or in situ cervical or anal
dysplasia

- History of malignant tumors other than KS or KSHV-MCD, unless:

- In complete remission for greater than or equal to 1 year for the time complete
remission was first documented

- Resected basal cell or squamous cell carcinoma of the skin

- In situ cervical or anal dysplasia

- Uncontrolled intercurrent illness including, but not limited to, uncontrolled active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- History of allergic reactions attributed to thalidomide, lenalidomide, or other
compounds of similar chemical or biologic composition to pomalidomide or other agents
used in study

- Because there is an unknown but potential risk for adverse events in nursing infants
secondary to treatment of the mother with pomalidomide, breastfeeding should be
discontinued if the mother is treated with pomalidomide. These potential risks may
also

apply to other agents used in this study.